Emerging Business Models in the Pharmaceutical Industries ...

More documents

Recommendations

Info

Benchmarking by Geographic Revenue Growth Europe had the highest percentage growth in revenues last year, but the much larger North American market is considered the pharma fortune market. 40 30 20 10 -10 Source: JSB Intelligence 0 Growth in revenues: Europe and North America( In Percentage) Europe North America AstraZeneca Eli Lilly Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 52 BMs Wyeth Merck Pfizer GSK JnJ
Large Spending on DTC All the Big Pharmas are spending considerable amounts on DTC, with Pfizer showing the highest spend. Other Big Pharmas have spent each over $100 million on DTC . Pharma companies are converting prescription drugs to DTC/OTC drugs through brand marketing. This model helps companies to avoid problems resulting from patent expiration. Benchmarking - by DTC Spending 700 600 500 400 300 200 100 0 DTC Spending by Big Pharmas (in million US$) Source: JSB Intelligence Pfizer Inc GlaxoSmithKline plc Merck & Co. Johnson & Johnson AstraZeneca plc Novartis Aventis Bristol Myers Squibb Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 53
Page 1 and 2: Emerging Business Models in the Pha
Page 3 and 4: Table of Contents Introduction…
Page 5 and 6: Acronyms Big Pharmas The top global
Page 7 and 8: Introduction Pharma Industry Overvi
Page 9 and 10: Market Segmentation Getting Blurred
Page 11 and 12: Growth in the Pharma Market The pha
Page 13 and 14: Factors Restraining Pharma Market R
Page 16 and 17: Geographic Overview Introduction No
Page 18 and 19: Trends in the Pharma Industry Short
Page 20 and 21: Long Term Strategies - Forward Inte
Page 22 and 23: Long Term Strategies - Targeted Tre
Page 24 and 25: Long Term Strategies - Biotech and
Page 26 and 27: Long Term Strategies - Biotech and
Page 28 and 29: Overview of the Network Model The n
Page 30 and 31: Outsourcing The network approach al
Page 32 and 33: Many of BMS's key drugs are from ot
Page 34 and 35: Growth in Semi Block Busters Even i
Page 36 and 37: Short Term Strategies - Pre- and Po
Page 38 and 39: Short Term Strategies Against Paral
Page 40 and 41: There are two main types of M&Q act
Page 42 and 43: The Revenue Model The market dynami
Page 44 and 45: Short Term and Mid Term Strategies
Page 46 and 47: Top 10 Pharma Companies - Major Mar
Page 48 and 49: Benchmarking - Top 20 Drugs by Sale
Page 50 and 51: Benchmarking by Percentage Growth i
Page 54 and 55: Rank 1 2 3 4 5 JnJ GSK Company Pfiz
Page 56 and 57: Altace® Biaxin® Zofran® Brands A
Page 58 and 59: Introduction Pfizer is the world's
Page 60 and 61: Introduction GlaxoSmithKline (GSK)
Page 62 and 63: Introduction Merck & Co. develops,
Page 64 and 65: Introduction Aventis’ core busine
Page 66 and 67: Introduction Bristol-Myers Squibb C
Page 68 and 69: Strategic Direction The company aim
Page 70 and 71: Strategic Direction JnJ has been fo
Page 72 and 73: 15% Percentage Revenues by Segment
Page 74 and 75: 12 10 8 6 4 2 0 The Americas Revenu
Page 76 and 77: 20 15 10 5 0 Novartis revenues by S
Page 78 and 79: Strategic Direction Eli Lilly focus
Page 80 and 81: New Revenue Models New revenue mode
Page 82: Contact Us For more information on

Emerging Business Models in the Pharmaceutical Industries ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?